Announced details
Treatment of esophageal cancer
All quality test items met the required standards in the 24-month stability study. The company stated that this will increase flexibility in inventory management and make a significant contribution to stable supply to medical institutions.
24-month shelf life (second commercial batch scheduled for shipment in 2027)
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
| Item | Details |
|---|---|
| Names of Products / Services Covered | Telomelysin® Injection (generic name: suratadenoturev; development code: OBP-301) |
| Launch date | Sales have begun. Start date: Not disclosed |
| Applicable area | Treatment of esophageal cancer |
| Registration number and expiry date | 24-month shelf life (second commercial batch scheduled for shipment in 2027) |
| Quantitative Effects | All quality test items met the required standards in the 24-month stability study. The company stated that this will increase flexibility in inventory management and make a significant contribution to stable supply to medical institutions. |
Items this document does not state (13)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.All quality test items met the required standards in the 24-month stability study. The company stated that this will increase flexibility in inventory management and contribute to stable supply to medical institutions.